Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01318252
Study type Interventional
Source Alcon Research
Contact
Status Completed
Phase Phase 2
Start date June 2011
Completion date October 2011

See also
  Status Clinical Trial Phase
Completed NCT02565173 - Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma Phase 3
Terminated NCT02226094 - Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension Phase 1/Phase 2
Recruiting NCT06016972 - Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients Phase 2
Terminated NCT01180062 - Safety Study of Latanoprost Slow Release Insert Phase 1
Completed NCT01917383 - A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Phase 2
Completed NCT01670266 - Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma Phase 1
Completed NCT02829996 - Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG Phase 2
Recruiting NCT06249152 - Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients Phase 2